miR-143和miR-145表达对胰腺癌根治术联合血管切除重建患者临床预后的意义  

Effect of miR-143 and miR-145 expression on clinical prognosis of patients with pancreatic cancer undergoing radical resection combined with revascularization

作　　者：郑新闻[1] 刘丹 李振平[1] 王常富 ZHENG Xin-wen;LIU Dan;LI Zhen-ping;WANG Chang-fu(Department of Invasive Technology,Sanmenxia Central Hospital,Sanmenxia 472000,China;Endoscopy Center,Sanmenxia Central Hospital,Sanmenxia 472000,China)

机构地区：[1]河南省三门峡市中心医院介入科,河南三门峡472000 [2]河南省三门峡市中心医院内镜中心,河南三门峡472000

出　　处：《中国现代普通外科进展》2019年第11期858-861,共4页Chinese Journal of Current Advances in General Surgery

摘　　要：目的:探究miR-143、miR-145表达对胰腺癌根治术联合血管切除重建患者临床预后的意义。方法:2016年3月—2018年4月,行胰腺癌根治术联合血管切除重建患者84例为治疗组,行健康体检者40例为对照组。提取miRNA,转录为cDNA,采用PCR技术观察血清miR-143、miR-145的表达。结果:胰腺癌患者血清miR-143、miR-145、癌胚抗原125、癌胚抗原199及癌胚抗原153不存在相关性(P>0.05),血清miR-143和miR-145存在相关性(P<0.05)。胰腺癌患者血清miR-143、miR-145表达与年龄、性别及肿瘤的分期、部位及直径不存在相关性(P>0.05);血清miR-143为胰腺癌发病的保护因素(P<0.05)。治疗后较治疗前血清miR-143、miR-145水平呈明显上升趋势,但仍低于对照组(P<0.05)。结论:胰腺癌根治术联合血管切除重建患者血清中miR-143或miR-145的表达明显低于健康对照组,miR-143是胰腺癌患者的保护因素,对判断胰腺癌根治术联合血管切除重建患者病情及预后有着重要意义。Objective:To investigate the effect of miR-143 and miR-145 expression on the clinical prognosis of patients with pancreatic cancer undergoing radical resection combined with revascularization.Methods:A total of 84 patients with pancreatic cancer radical resection combined with revascularization were enrolled in the hospital from March to May 2018,2016.A total of 40 healthy controls in the same period in the hospital were selected.All patients underwent radical pancreatic cancer.Surgery,in which the patients in the study group were treated with radical resection and reconstruction techniques based on radical surgery.The miRNA was extracted according to the kit procedure and requirements,and transcribed into cDNA.At the same time,miR-143 was used in the serum of the study subjects by PCR,the expression of miR-145.Results:There was no correlation between miR-143,miR-145 carcinoembryonic antigen 125,carcinoembryonic antigen 199 and carcinoembryonic antigen 153 in the serum of patients with pancreatic cancer(P>0.05),but the results showed that patients with serum miR-143 and miR There was a correlation of-145(P<0.05).There was no correlation between serum miR-143 and miR-145 in patients with pancreatic cancer and their age,gender and stage,location and diameter of the tumor(P>0.05).The general data of age,sex and other diseases of pancreatic cancer patients were not directly related to the incidence of pancreatic cancer.Correlation,and miR-145 was not associated with the occurrence of pancreatic cancer(P>0.05),but serum miR-143 was a protective factor for the onset of pancreatic cancer patients(P<0.05).Patients were compared with the control group for pancreatic cancer after treatment.The expression of miR-143 and miR-145 in the serum of patients was significantly decreased(P<0.05).However,the levels of miR-143 and miR-145 in the serum after treatment were significantly higher than those in the healthy group(P<0.05).Conclusion:The expression of miR-143 or miR-145 in patients with pancreatic cancer combined with revasc

关 键 词：胰腺癌 血管重建 MIR-143 MIR-145 

分 类 号：R735.9[医药卫生—肿瘤]